Overview

Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis

Status:
Completed

Trial end date:
2017-06-28

Target enrollment:

Participant gender:

Summary

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Symptomatic Ulcerative Colitis Patients with Moderate to Severe Disease Activity

Phase:

Phase 2

Details

Lead Sponsor:

Topivert Pharma Ltd

Treatments:

Pharmaceutical Solutions